8-K: Interpace Biosciences Reports Strong Q4, Full Year 2025 Results

Interpace Biosciences announced its fourth quarter and full year 2025 financial results, highlighting strong thyroid segment growth and a significant non-cash tax benefit.

Summary

• Q4 2025 revenue was $9.2 million, a decrease of 26% from Q4 2024, but an increase of 20% from Q4 2024 Pro Forma.
• Full Year 2025 revenue was $38.7 million, a decrease of 18% from FY 2024, but an increase of 17% from FY 2024 Pro Forma.
• Q4 2025 income from continuing operations was $22.8 million, benefiting from a one-time, non-cash tax-related accounting adjustment.
• Full Year 2025 income from continuing operations was $25.0 million, benefiting from a one-time, non-cash tax-related accounting adjustment.
• Q4 2025 thyroid volume increased 11% year-over-year, and full year 2025 thyroid volume increased 13% year-over-year.
• Q4 2025 thyroid revenue increased 14% year-over-year, and full year 2025 thyroid revenue increased 21% year-over-year.
• The company completed its transition to a thyroid-only diagnostics testing company in 2025, discontinuing PancraGEN.
• Debt was fully paid off in Q4 2025, and cash availability increased by $4.3 million year-over-year.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, driven by strong thyroid segment growth, significant operational efficiencies, and a strengthened balance sheet, despite the one-time nature of the tax benefit.

Positives

• Q4 2025 thyroid revenue increased 14% year-over-year, and full year 2025 thyroid revenue increased 21% year-over-year.
• Q4 2025 thyroid test volume increased 11% year-over-year, and full year 2025 thyroid test volume increased 13% year-over-year.
• Income from continuing operations was significantly boosted by a one-time, non-cash tax-related accounting adjustment, reaching $22.8 million in Q4 and $25.0 million for the full year.
• Average thyroid revenue per test increased 5% year-over-year.
• Days sales outstanding (DSO) decreased 19% year-over-year, indicating improved cash collection efficiency.
• Turnaround time decreased 20% year-over-year, enhancing service delivery.
• Average volume per account increased 6% year-over-year, and the number of accounts increased 9% year-over-year.
• The percentage of new accounts converted to recurring accounts increased 10% year-over-year.
• All company debt was fully paid off in Q4 2025, strengthening the balance sheet.
• Cash and cash equivalents increased to $2,505 thousand at December 31, 2025, from $1,461 thousand at December 31, 2024.
• Total stockholders' equity moved from a deficit of $(2,217) thousand in 2024 to a positive $22,363 thousand in 2025.

Negatives

• Q4 2025 total revenue decreased 26% to $9.2 million from $12.4 million in Q4 2024 (though up 20% pro forma after discontinuing PancraGEN).
• Full year 2025 total revenue decreased 18% to $38.7 million from $46.9 million in FY 2024 (though up 17% pro forma after discontinuing PancraGEN).
• Adjusted EBITDA decreased to $1.7 million in Q4 2025 from $2.2 million in Q4 2024.
• Adjusted EBITDA decreased to $5.4 million in FY 2025 from $8.7 million in FY 2024.
• Cash collections decreased to $9.6 million in Q4 2025 from $11.2 million in Q4 2024.
• Cash collections decreased to $41.7 million in FY 2025 from $43.6 million in FY 2024.

Risks

• Estimates of future revenue, net income, and adjusted EBITDA may prove to be materially inaccurate.
• Preliminary unaudited financial results are subject to audit review and adjustments.
• The company has a prior history of operating losses.
• The company's ability to adequately finance its business is a risk.
• Dependence on sales and reimbursements from clinical services, including reliance on third parties to process and transmit claims to payers.
• The adverse impact of any delay, data loss, or other disruption in processing or transmitting claims.
• Revenue recognition is based in part on estimates for future collections, which estimates may prove to be incorrect.

Future Outlook

Interpace is positioned to accelerate execution in 2026 with a streamlined, thyroid-only operating model and strong commercial momentum. The company aims to scale thyroid test volume through deeper adoption within existing accounts and ongoing account growth, drive productivity via automation and operational discipline, and deliver approximately 16% year-over-year thyroid revenue growth.

Management Comments

• "The Company delivered strong thyroid performance in the fourth quarter, capping a transformational year as we completed our transition to a thyroid-only diagnostics testing company." Chris McCarthy, CFO.
• "Our strong financial position enabled continued investments in laboratory operational efficiency, leveraging AI and automation as part of our digital strategy." Chris McCarthy, CFO.
• "2025 marked a pivotal year for Interpace as we successfully navigated the PancraGEN discontinuation and emerged as a focused thyroid diagnostics company." Tom Burnell, President and CEO.
• "Our fourth quarter results demonstrate the resilience of our business model and the strength of our comprehensive thyroid testing platform." Tom Burnell, President and CEO.
• "We believe our combination approach—ThyGeNEXT for mutation detection and ThyraMIRv2 for microRNA pathway insights—helps provide physicians the confidence and clarity they need to make informed patient-management decisions." Tom Burnell, President and CEO.

Industry Context

StockSavvy.ai notes that Interpace Biosciences' strategic pivot to a thyroid-only diagnostics focus aligns with a broader trend in the specialized diagnostics sector towards niche market leadership and operational efficiency. The emphasis on AI and automation for laboratory efficiency reflects industry-wide efforts to reduce costs and improve turnaround times in a competitive diagnostic landscape.

Comparison to Industry Standards

• The 14% Q4 and 21% full-year thyroid revenue growth rates are strong, potentially outperforming general diagnostic market growth, which typically ranges from mid-single digits to low double-digits for established players.
• The 19% decrease in Days Sales Outstanding (DSO) suggests efficient billing and collection practices, which is a positive indicator compared to industry averages that can vary widely but often face challenges with complex reimbursement landscapes.
• The 20% decrease in turnaround time for tests is a significant operational improvement, potentially positioning Interpace favorably against competitors like Veracyte (Afirma) or Exact Sciences (ThyraMIR) by offering faster results to physicians and patients.

Stakeholder Impact

• Shareholders: Positive impact due to improved financial performance, strengthened balance sheet (debt repayment, increased cash, positive equity), and clear strategic focus on a growing segment. The one-time tax benefit significantly boosted reported income.
• Employees: Potential positive impact from investments in laboratory operational efficiency, AI, and automation, suggesting a focus on modernizing operations and potentially upskilling.
• Customers (Physicians/Patients): Positive impact from decreased turnaround time (20% year-over-year), providing faster and more confident diagnostic results for thyroid cancer management. Increased account numbers and volume per account suggest growing physician adoption.
• Creditors: Positive impact from the full repayment of debt in Q4 2025, significantly reducing financial risk.

Next Steps

• Accelerate execution in 2026.
• Scale thyroid test volume through deeper adoption within existing accounts and ongoing account growth.
• Drive productivity gains through automation and operational discipline.
• Deliver on previously provided guidance of approximately 16% year-over-year thyroid revenue growth.

Key Dates

Recommendation

The company has successfully executed a strategic pivot to a high-growth, specialized thyroid diagnostics market, demonstrating strong year-over-year growth in both thyroid revenue (21%) and test volume (13%) for the full year 2025. Operational efficiencies, including reduced DSO and turnaround times, indicate robust management. The full repayment of debt and a significant increase in cash and equity dramatically strengthen the balance sheet, reducing financial risk. While the large income from continuing operations is partly due to a one-time tax adjustment, the underlying business performance and future outlook for 16% thyroid revenue growth are compelling. These factors suggest strong potential for future value creation.

Keywords

Interpace Biosciences, ThyGeNEXT, ThyraMIRv2, thyroid diagnostics, molecular diagnostics, financial results, Q4 2025, full year 2025, biotechnology, healthcare, diagnostics testing, revenue growth, debt repayment, deferred tax asset, SEC filing